Related references
Note: Only part of the references are listed.The role of PI3K/Akt signaling pathway in non-physiological shear stress-induced platelet activation
Zengsheng Chen et al.
ARTIFICIAL ORGANS (2019)
Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases
Jens J. Posma et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Do methodological differences account for the current controversy on tissue factor expression in platelets?
Marta Brambilla et al.
PLATELETS (2018)
Effects of upstream shear forces on priming of platelets for downstream adhesion and activation
Shekh M. Rahman et al.
ACTA BIOMATERIALIA (2018)
Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation
Christina Ji-Young Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Cathelicidins prime platelets to mediate arterial thrombosis and tissue inflammation
Joachim Pircher et al.
NATURE COMMUNICATIONS (2018)
Intracellular platelet signalling as a target for drug development
Gemma Vilahur et al.
VASCULAR PHARMACOLOGY (2018)
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction
Oliver Borst et al.
BLOOD ADVANCES (2018)
First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans
Frantisek Nehaj et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
Inflammatory cell content of coronary thrombi is dependent on thrombus age in patients with ST-elevation myocardial infarction
Wessel W. Fuijkschot et al.
JOURNAL OF CARDIOLOGY (2017)
Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation
A. Achilles et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation
B. Steppich et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2017)
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
J. W. Eikelboom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding
Pancras C. Wong et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Jose A. Lopez-Lopez et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Jose A. Lopez-Lopez et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome
Bahar Artim-Esen et al.
SCIENTIFIC REPORTS (2017)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
The Perseus computational platform for comprehensive analysis of (prote)omics data
Stefka Tyanova et al.
NATURE METHODS (2016)
Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding
Pasquale Pignatelli et al.
PHARMACOLOGICAL RESEARCH (2016)
Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis
Tobias Petzold et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies
Elisabeth Perzborn et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2015)
Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response invivo
L. Ivanciu et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers
Noa Zemer-Wassercug et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2015)
Time- and compartment-resolved proteome profiling of the extracellular niche in lung injury and repair
Herbert B. Schiller et al.
MOLECULAR SYSTEMS BIOLOGY (2015)
NETWORK META-ANALYSIS OF ORAL ANTICOAGULANTS FOR PRIMARY PREVENTION, TREATMENT AND SECONDARY PREVENTION OF VENOUS THROMBOEMBOLIC DISEASE, AND FOR PREVENTION OF STROKE IN ATRIAL FIBRILLATION
J. A. Lopez-Lopez et al.
VALUE IN HEALTH (2015)
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Giulia Magnani et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2015)
Characterization of Thrombin-Bound Dabigatran Effects on Protease-Activated Receptor-1 Expression and Signaling In Vitro
Buxin Chen et al.
MOLECULAR PHARMACOLOGY (2015)
New insights into the spatiotemporal localization of prothrombinase in vivo
Lacramioara Ivanciu et al.
BLOOD (2014)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Wolfgang Mueck et al.
CLINICAL PHARMACOKINETICS (2014)
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
Kenneth W. Mahaffey et al.
EUROPEAN HEART JOURNAL (2014)
A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel
Mark R. Thomas et al.
PLATELETS (2014)
Biased signaling of protease-activated receptors
Peishen Zhao et al.
FRONTIERS IN ENDOCRINOLOGY (2014)
Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors
Ramin Artang et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Hydrogen Sulfide-Releasing Aspirin Derivative ACS14 Exerts Strong Antithrombotic Effects In Vitro and In Vivo
Joachim Pircher et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Pierluigi Tricoci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
David A. Morrow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of the Factor Xa Inhibitor Rivaroxaban on Arterial Thrombosis in Wild-Type and Apolipoprotein E-Deficient Mice
Nana-Maria Wagner et al.
THROMBOSIS RESEARCH (2012)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Platelet Matrix Metalloprotease-1 Mediates Thrombogenesis by Activating PAR1 at a Cryptic Ligand Site
Vishal Trivedi et al.
CELL (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Protease-activated receptors: Contribution to physiology and disease
VS Ossovskaya et al.
PHYSIOLOGICAL REVIEWS (2004)
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions
JA Coppinger et al.
BLOOD (2004)
A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy
S Kamath et al.
EUROPEAN HEART JOURNAL (2002)
A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation
S Kamath et al.
BLOOD COAGULATION & FIBRINOLYSIS (2002)
Share Paper
